CP 809101 hydrochloride
Potent and selective 5-HT2C receptor agonist (pEC50 values are 9.96, 7.19 and 6.81 for human 5-HT2C, 5-HT2B and 5-HT2A receptors respectively). Displays antipsychotic activity; suppresses condition avoidance responding (CAR) and inhibits PCP and amphetamine-stimulated hyperactivity in rats following subcutaneous administration.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 341.24. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.93 mL||14.65 mL||29.3 mL|
|5 mM||0.59 mL||2.93 mL||5.86 mL|
|10 mM||0.29 mL||1.47 mL||2.93 mL|
|50 mM||0.06 mL||0.29 mL||0.59 mL|
References are publications that support the products' biological activity.
Siuciak et al (2007) CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 52 279 PMID: 16949622
Kalgutkar et al (2007) Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation. Drug Metab.Dispos. 35 848 PMID: 17344339
Jensen et al (2013) Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive J.Med.Chem 56 1211 PMID: 23301527
If you know of a relevant reference for CP 809101 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: CP 809101 hydrochloride, supplier, Potent, selective, 5-HT2C, agonists, Serotonin, Receptors, CP809101, hydrochloride, 5-HT2C, Receptors, 5-HT2C, Receptors, Tocris Bioscience
5 Citations for CP 809101 hydrochloride
Citations are publications that use Tocris products. Selected citations for CP 809101 hydrochloride include:
Goda et al (2013) Serotonergic hallucinogens differentially modify gamma and high frequency oscillations in the rat nucleus accumbens. Psychopharmacology (Berl) 228 271 PMID: 23525524
Schulz et al (2012) First and second generation antipsychotics influence hippocampal gamma oscillations by interactions with 5-HT3 and D3 receptors. Br J Pharmacol 167 1480 PMID: 22817643
Austgen et al (2012) 5-hydroxytryptamine 2C receptors tonically augment synaptic currents in the nucleus tractus solitarii. Oncotarget 108 2292 PMID: 22855775
Yamamoto (2017) Loss of GluN2D subunit results in social recognition deficit, social stress, 5-HT2C receptor dysfunction, and anhedonia in mice. Neuropharmacology 112 188 PMID: 27480795
Gerhold et al (2015) Pronociceptive and Antinociceptive Effects of Buprenorphine in the Spinal Cord Dorsal Horn Cover a Dose Range of Four Orders of Magnitude. J Neurosci 35 9580 PMID: 26134641
Do you know of a great paper that uses CP 809101 hydrochloride from Tocris? If so please let us know.
CP 809101 hydrochloride Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.